# A Phase III Study of Re-Irradiation in Recurrent Glioblastoma

> **NCT01830101** · PHASE3 · WITHDRAWN · sponsor: **AHS Cancer Control Alberta**

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** TMZ plus concurrent re-irradiation
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01830101
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-02
- **Primary completion:** 2015-05
- **Final completion:** 2017-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study will not be proceeding due to lack of funding from anticipated sources
- **Last updated:** 2016-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830101, "A Phase III Study of Re-Irradiation in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01830101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*